Загрузка...
Clinical Management of Adverse Events Associated with Lorlatinib
Lorlatinib is a novel, highly potent, brain‐penetrant, third‐generation ALK/ROS1 tyrosine kinase inhibitor (TKI), which has broad‐spectrum potency against most known resistance mutations that can develop during treatment with crizotinib and second‐generation ALK TKIs. The safety profile of lorlatini...
Сохранить в:
| Опубликовано в: : | Oncologist |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley & Sons, Inc.
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6693708/ https://ncbi.nlm.nih.gov/pubmed/30890623 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0380 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|